Stada to commercialize Rowiren in Nordic region

Stada to commercialize Rowiren in Nordic region

We are very excited to announce our new collaboration with STADA Nordic. This new partnership will include exclusive commercialization of Rowiren® in Denmark, Finland, Norway and Sweden.

Rowiren® enables natural relief of minor muscle and joint pain as well as minor peripheral circulatory disorders, and is expected to provide an entirely new treatment option in the Nordic markets, which are heavily dominated by synthetic topical analgesics.

Rowiren® shows many benefits and is an excellent solution for those who prefer a natural, clinically tested medicine,

emphasized Maja Frelih, PharmD, Managing Director Medis Consumer Health.

The synergy was also recognized by STADA Nordic:

True to STADA’s position as a partner in consumer healthcare, we are delighted to work with Medis Consumer Health to offer consumers and healthcare professionals throughout the Nordic region a new treatment option, 

commented Inge-Merete Larsen, Managing Director of STADA Nordic.

At Medis we are proud that STADA Nordic will take over the commercialisation of an efficient natural OTC medicine Rowiren®, recently developed by Medis. It is exciting to see that together we will give patients with pain a novel local treatment that Rowiren® brings,

emphasized Martina Perharič, CEO at Medis.

Related news